Press Release | March 2, 2026
Skyhawk Announces Australia’s Therapeutic Goods Administration Has Determined SKY-0515 for Huntington’s Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Read More
Press Release | February 24, 2026
Nu-Tek BioSciences to Highlight Animal-Origin-Free Peptones, Supply Chain Strength at DCAT Week 2026
Read More
Press Release | February 24, 2026
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
Read More
Press Release | February 9, 2026
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Read More
Press Release | January 23, 2026
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
Read More
Press Release | January 21, 2026
Nu-Tek BioSciences Reinforces Global Supply Leadership with Halal Certification Renewal
Read More
News | January 15, 2026
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
Read More
Press Release | January 8, 2026
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Read More
Press Release | January 5, 2026
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Read More
